Metraipolis › archive › dc_dbc620d3948d

Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases — Europe PMC PMID:31725785

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/31725785
DOI
10.1371/journal.pone.0225239
License (as archived)
CC0-1.0
Archived
2026-11-10T02:19:54.008Z
SHA-256 of the archived text
fec8bb97ffed0d906d3c2b3b285813b6ec0af65ebdf562f50a14a6750bfac315
Stable URL of this page
https://metraipolis.com/documento/dc_dbc620d3948d

How to cite

Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases — Europe PMC PMID:31725785 — Europe PMC (en), https://europepmc.org/article/MED/31725785 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_dbc620d3948d (Metraipolis archive dc_dbc620d3948d, sha256 fec8bb97ffed0d906d3c2b3b285813b6ec0af65ebdf562f50a14a6750bfac315)
BibTeX
@misc{dcdbc620d3948d,
  title = {Comparison of potential drug-drug interactions with metabolic syndrome medications detected by two databases — Europe PMC PMID:31725785},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/31725785},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_dbc620d3948d; sha256 fec8bb97ffed0d906d3c2b3b285813b6ec0af65ebdf562f50a14a6750bfac315},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/31725785. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Drug-drug interactions (DDIs) are one of the most common drug-related problems. Recently, electronic databases have drug interaction tools to search for potential DDIs, for example, Micromedex and Drugs.com. However, Micromedex and Drugs.com have different abilities in detecting potential DDIs, and this might cause misinformation to occur between patients and health care providers. Methods and findings: The aim of this study was to compare the ability of Micromedex and Drugs.com to detect potential DDIs with metabolic syndrome medications using the drug list from the U-central database, King Chulalongkorn Memorial Hospital in April 2019. There were 90 available drugs for the treatment of the metabolic syndrome and its associated complications, but six were not found in the Micromedex and Drugs.com databases; therefore, only 84 items were used in the present study. There were 1,285 potential DDI pairs found by the two databases. Micromedex reported DDIs of 724 pairs, while, Drugs.com reported 1,122 pairs. For the severity of the potential DDI reports, the same severity occurred between the two databases of 481 pairs (37.43%) and a different severity for 804 pairs (62.57%). Conclusion: Drugs.com had a higher sensitivity to detect potential DDIs by approximately 1.5-fold, but Micromedex supplied more informative documentation for the severity classification. Therefore, pharmacists should use at least two databases to evaluate potential DDIs and determine the appropriate drug regimens for physician communications and patient consultations.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2019 (prima pubblicazione 2019-11-14).
Identificativi: PMID 31725785 · PMCID PMC6855424 · DOI 10.1371/journal.pone.0225239.
Descrittori MeSH principali: Drug Interactions.
Pagina: https://europepmc.org/article/MED/31725785 — https://doi.org/10.1371/journal.pone.0225239. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-10T02:17:05.382Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.